European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

A Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients with advanced non–small cell lung cancer and activating EGFR exon 20 insertion mutations has been submitted to the European Medicines Agency.

Related Keywords

Janssen Cilag Gmb ,Martin Vogel ,Kiran Patel ,Janssen Research Development ,European Medicines Agency For Rybrevant ,European Medicines Agency ,Drug Administration ,Janssen Pharmaceutical Companies Of Johnson ,European Commission ,Area Lead Oncology ,Janssen Cilag Gmbh ,Janssen Research ,Janssen Pharmaceutical Companies ,Epidermal Growth Factor Receptor ,Amivantimab ,Chemotherapy ,Egfr Exon 20 Insertion Mutation ,Lung ,Non Small Cell Lung Cancer Nsclc ,